Patents by Inventor Steven Anthony Raw

Steven Anthony Raw has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITIONS COMPRISING AZD9291
    Publication number: 20220395502
    Abstract: The present invention relates to pharmaceutical compositions suitable for oral administration, and more particularly to pharmaceutical compositions, including pharmaceutical tablet compositions, containing N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide (“AZD9291”) or a pharmaceutically acceptable salt thereof, wherein such compositions comprise a certain amount of microcrystalline cellulose and at least one other pharmaceutical diluent.
    Type: Application
    Filed: April 26, 2022
    Publication date: December 15, 2022
    Inventors: Cindy FINNIE, Steven Anthony RAW, David WILSON
  • PHARMACEUTICAL COMPOSITIONS COMPRISING AZD9291
    Publication number: 20200360378
    Abstract: The present invention relates to pharmaceutical compositions suitable for oral administration, and more particularly to pharmaceutical compositions, including pharmaceutical tablet compositions, containing N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide (“AZD9291”) or a pharmaceutically acceptable salt thereof, wherein such compositions comprise a certain amount of microcrystalline cellulose and at least one other pharmaceutical diluent.
    Type: Application
    Filed: August 4, 2020
    Publication date: November 19, 2020
    Inventors: Cindy FINNIE, Steven Anthony RAW, David WILSON
  • PHARMACEUTICAL COMPOSITIONS COMPRISING AZD9291
    Publication number: 20190111057
    Abstract: The present invention relates to pharmaceutical compositions suitable for oral administration, and more particularly to pharmaceutical compositions, including pharmaceutical tablet compositions, containing N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide (“AZD9291”) or a pharmaceutically acceptable salt thereof, wherein such compositions comprise a certain amount of microcrystalline cellulose and at least one other pharmaceutical diluent.
    Type: Application
    Filed: November 20, 2018
    Publication date: April 18, 2019
    Applicant: AstraZeneca AB
    Inventors: Cindy FINNIE, Steven Anthony RAW, David WILSON
  • Pharmaceutical compositions comprising AZD9291
    Patent number: 10183020
    Abstract: The present invention relates to pharmaceutical compositions suitable for oral administration, and more particularly to pharmaceutical compositions, including pharmaceutical tablet compositions, containing N-(2-{2-dimethylaminoethyl-methyl-amino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide (“AZD9291”) or a pharmaceutically acceptable salt thereof, wherein such compositions comprise a certain amount of microcrystalline cellulose and at least one other pharmaceutical diluent.
    Type: Grant
    Filed: January 2, 2015
    Date of Patent: January 22, 2019
    Assignee: AstraZeneca AB
    Inventors: Cindy Finnie, Steven Anthony Raw, David Wilson
  • PHARMACEUTICAL COMPOSITIONS COMPRISING AZD9291
    Publication number: 20160324854
    Abstract: The present invention relates to pharmaceutical compositions suitable for oral administration, and more particularly to pharmaceutical compositions, including pharmaceutical tablet compositions, containing N-(2-{2-dimethylaminoethyl-methyl-amino}-4-methoxy-5-[4-(1-methylindol-3-yppyrimidin-2-yl]amino phenyl)prop-2-enamide (“AZD9291”) or a pharmaceutically Cacceptable salt thereof, wherein such compositions comprise a certain amount of microcrystalline cellulose and at least one other pharmaceutical diluent.
    Type: Application
    Filed: January 2, 2015
    Publication date: November 10, 2016
    Applicant: AstraZeneca AB
    Inventors: Cindy FINNIE, Steven Anthony RAW, David WILSON
  • Process for the preparation of novel pyridopyrazines as mTOR kinase inhibitors
    Patent number: 8198441
    Abstract: There is provided a process for the preparation of a compound of Formula 1, the use of said process in the preparation of a compound of Formula 5 or a phosphate, sulphate, hydrogensulphate, malate, citrate, tartrate or fumarate salt thereof, and the use of the fumarate salt in a composition for use in therapy.
    Type: Grant
    Filed: June 18, 2009
    Date of Patent: June 12, 2012
    Assignee: AstraZeneca AB
    Inventors: Helen Blade, Gwydion Huw Churchill, Angela Charlotte Currie, Benjamin Charles Dobson, Martin Neal Kenworthy, Lyn Powell, Steven Anthony Raw, Peter Samuel Hynes
  • COMPOSITION AND PROCESS - 356
    Publication number: 20090318434
    Abstract: There is provided a process for the preparation of a compound of Formula 1, the use of said process in the preparation of a compound of Formula 5 or a phosphate, sulphate, hydrogensulphate, malate, citrate, tartrate or fumarate salt thereof, and the use of the fumarate salt in a composition for use in therapy.
    Type: Application
    Filed: June 18, 2009
    Publication date: December 24, 2009
    Applicant: AstraZeneca AB
    Inventors: Helen Blade, Gwydion Huw Churchill, Angela Charlotte Currie, Benjamin Charles Dobson, Martin Neal Kenworthy, Lyn Powell, Steven Anthony Raw, Peter Samuel Hynes